Viracta Therapeutics Past Earnings Performance
Past criteria checks 0/6
Viracta Therapeutics has been growing earnings at an average annual rate of 4.4%, while the Biotechs industry saw earnings growing at 13.6% annually.
Key information
4.4%
Earnings growth rate
79.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -1,697.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Viracta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -45 | 15 | 34 |
| 31 Mar 24 | 0 | -48 | 17 | 36 |
| 31 Dec 23 | 0 | -51 | 17 | 33 |
| 30 Sep 23 | 0 | -48 | 18 | 31 |
| 30 Jun 23 | 0 | -53 | 25 | 30 |
| 31 Mar 23 | 0 | -51 | 25 | 28 |
| 31 Dec 22 | 0 | -49 | 24 | 26 |
| 30 Sep 22 | 0 | -50 | 23 | 27 |
| 30 Jun 22 | 0 | -47 | 16 | 27 |
| 31 Mar 22 | 0 | -46 | 16 | 26 |
| 31 Dec 21 | 0 | -115 | 15 | 24 |
| 30 Sep 21 | 0 | -110 | 14 | 20 |
| 30 Jun 21 | 0 | -99 | 11 | 16 |
| 31 Mar 21 | 0 | -94 | 8 | 14 |
| 31 Dec 20 | 0 | -19 | 5 | 13 |
| 31 Dec 19 | 0 | -14 | 3 | 9 |
| 31 Dec 18 | 1 | -10 | 2 | 6 |
Quality Earnings: RYI is currently unprofitable.
Growing Profit Margin: RYI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RYI is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare RYI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RYI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.6%).
Return on Equity
High ROE: RYI has a negative Return on Equity (-1697.34%), as it is currently unprofitable.